Atracurium - Dose, Indications, Contraindications, ...

Atracurium binds to the cholinergic receptors and blocks the neuromuscular transmission.

It is used in the following situations:

  • As an adjunct to general anesthesia
  • To facilitate endotracheal intubation
  • As a muscle relaxant during surgery and mechanical ventilation in a sedated patient.

Off-Label Use of Atracurium in Adults:

  • ARDS (Acute respiratory distress syndrome)
  • Shivering secondary to therapeutic hypothermia after a cardiac Arrest

Atracurium Dose in Adults

Dose in the treatment of Intensive care unit paralysis (off-label dosing):

  • Initial bolus of 0.4 - 0.5 mg/kg intravenous, followed by 4 - 20 mcg/kg/minute (0.24 - 1.2 mg/kg/hour)

Dose in the treatment of Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation (as an adjunct to general anesthesia):

  • Intravenous bolus of 0.4 - 0.5 mg/kg initially
  • 0.08 to 0.1 mg/kg administered 20 - 45 minutes after the initial dose to maintain neuromuscular block
  • A repeat dose at 15 - 25 minute intervals may be administered if needed.

Note: Because of the increased risk of hypotension, patients with significant cardiovascular disease may be administered a lower initial dose i.e. 0.3 - 0.4 mg/kg. The dose should also be reduced in asthmatics.

  • Initial dose after succinylcholine for intubation (balanced anesthesia):

    • 0.3 - 0.4 mg/kg
  • Pre-treatment or priming:

    • 10% of the intubating dose (0.04 - 0.05 mg/kg) is given 2 - 4 minutes before the larger second dose.
  • Maintenance infusion for continued surgical relaxation during extended surgical procedures:

    • A continuous infusion at a rate of 9 - 10 mcg/kg/minute (0.54 - 0.6 mg/kg/hour) may be administered initially.
    • The block usually is maintained at a rate of 5 - 9 mcg/kg/minute (0.3 - 0.54 mg/kg/hour) under balanced anesthesia
    • The usual range is 2 - 15 mcg/kg/minute (0.12 - 0.9 mg/kg/hour)

Atracurium Dose in Children

Dose in the treatment of neuromuscular blockade as an adjunct to surgical anesthesia:

  • Initial dose in Infants and Children less than 2 years of age:
    • 0.3 - 0.4 mg/kg intravenous (to maintain adequate neuromuscular blockade, additional doses of 0.3 - 0.4 mg/kg may be repeated as needed)
  • Initial dose in children older than 2 years and Adolescents:
    • 0.4 - 0.5 mg/kg orally once followed by 0.08 - 0.1 mg/kg 20 - 45 minutes after initial dose to maintain neuromuscular block (the dose may be repeated at 15 - 25 minute intervals as needed)
  • Maintenance infusion (for continued surgical relaxation during extended surgical procedures):

    • Infants and Children less than 2 years of age:
      • 6 - 14 mcg/kg/minute as a continuous intravenous infusion (0.4 - 0.8 mg/kg/hour).
    • Children older than 2 years and Adolescents:
      • 9 - 10 mcg/kg/minute initially as a continuous intravenous infusion (0.54 - 0.6 mg/kg/hour)
      • Neuromuscular block is usually maintained at a rate of 5 - 9 mcg/kg/minute (0.3 - 0.54 mg/kg/hour)
      • The usual range is 2 - 15 mcg/kg/minute (0.1 - 0.9 mg/kg/hour)

Dose in the treatment of paralysis in the ICU setting in sedated patients:

  • 0.3 - 0.6 mg/kg intravenous as an initial bolus, followed by a continuous Intravenous infusion of 5 - 28 mcg/kg/minute (0.3 - 1.7 mg/kg/hour).

Pregnancy Risk Factor C

  • When administered during cesarean section, small amounts of the drug have been shown to pass the placental boundary.
  • Animal studies have shown adverse fetal events.

Use of Atracurium while breastfeeding

  • It is best to avoid breastfeeding while using it.

Atracurium Dose in Renal Disease:

  • The manufacturer has not recommended any dose adjustment in patients with renal disease.

Atracurium Dose in Liver Disease:

  • The manufacturer has not recommended any dose adjustment in patients with liver disease.

Side effects of atracurium:

Frequency not defined.

Mild adverse reactions may be seen secondary to the release of histamine.

Less Common Side Effects of Atracurium Include:

  • Cardiovascular:
    • Flushing

Contraindication to Atracurium Include:

  • Allergy to atracurium and any component of the formulation
  • There is a known allergy to benzyl alcohol.

Warnings and Precautions

  • Anaphylaxis

    • It is possible to have severe allergic reactions, including anaphylactic reactions that can lead to death.
    • Epinephrine should always be available in the injection settings to allow immediate use.
    • Patients who have had anaphylactic reactions in the past should be cautious about taking this drug.
  • Bradycardia

    • It is possible to develop Bradycardia. It is more common when using atracurium than other neuromuscular blockers.
  • Burn injury

    • Atracurium may not be effective for patients with burns greater than 20% of their body surface.
    • After wound healing, resistance to atracurium can persist for many months.
  • These conditions may reduce the neuromuscular-blocking effects of atracurium:

    • Respiratory alkalosis
    • Hypercalcemia
    • Demyelinating lesion
    • Peripheral neuropathies
    • Denervation
    • Muscle trauma
  • These conditions may increase the neuromuscular blocking effects of atracurium.

    • Hypermagnesemia and severe hypocalcemia are examples of electrolyte abnormalities.
    • Neuromuscular diseases
    • Metabolic acidosis
    • Respiratory acidosis
    • Eaton-Lambert syndrome
    • Myasthenia gravis

Atracurium: Drug Interactions

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

 

Risk Factor C (Monitor therapy).

Acetylcholinesterase inhibitors

May reduce the neuromuscular-blocking effects of Neuromuscular Blocking Agents (Nondepolarizing).

Aminoglycosides

May increase the effect of Neuromuscular Blocking Agents on the respiratory system.

Bacitracin (Systemic).

May increase the neuromuscular-blocking effects of Neuromuscular Blocking agents.

Botulinum Toxin-Containing Product

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Bromperidol

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Calcium Channel Blockers

May increase the neuromuscular-blocking effects of Neuromuscular Blocking agents (Nondepolarizing).

Capreomycin

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

CarBAMazepine

This may decrease serum concentrations of Neuromuscular-Blocking Agents.

Cardiac Glycosides

Neuromuscular-blocking agents can enhance Cardiac Glycosides.

Clindamycin (Topical).

May increase the neuromuscular-blocking effects of neuromuscular blocking agents.

CycloSPORINE Systemic

May increase the neuromuscular-blocking effects of neuromuscular blocking agents.

Fosphenytoin - Phenytoin

May decrease the neuromuscular-blocking effects of Neuromuscular Blocking agents (Nondepolarizing). Fosphenytoin - Phenytoin could increase the neuromuscular blocking effects of Neuromuscular-Blocking Agents. Fosphenytoin–Phenytoin could decrease serum levels of Neuromuscular Blocking Agents (Nondepolarizing).

Inhalational Anesthesia

May increase the neuromuscular-blocking effects of Neuromuscular Blocking agents (Nondepolarizing).

Ketorolac, (Nasal).

This may increase the toxic/adverse effects of Neuromuscular Blocking Agents (Nondepolarizing). Patients who have used this combination have experienced episodes of apnea.

Ketorolac Systemic

This may increase the toxic/adverse effects of Neuromuscular Blocking Agents (Nondepolarizing). Patients who have used this combination have experienced episodes of apnea.

Lincosamide Antbiotics

May increase the neuromuscular-blocking effects of neuromuscular blocking agents.

Lithium

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Local Anesthesia

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents. Exceptions: Benzocaine, Benzydamine, Cocaine (Topical); Dibucaine. Dyclonine. Hexylresorcinol. Lidocaine.

Loop Diuretics

May reduce the neuromuscular-blocking effects of neuromuscular blocking Agents. Neuromuscular blocking agents may have a neuromuscular blocking effect that loop diuretics can increase.

Magnesium Salts

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Minocycline

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Pholcodine

Can increase the toxic/adverse effects of Neuromuscular Blocking Agents. Anaphylaxis was reported in particular.

Procainamide

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

QuiNIDine

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Spironolactone

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents (Nondepolarizing).

Tetracyclines

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Thiazide and Thiazide -Like Diuretics

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents (Nondepolarizing).

Trimebutine

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents (Nondepolarizing).

Vancomycin

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Risk Factor D (Consider therapy modifications)

Colistimethate

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Systemic Corticosteroids

Neuromuscular-Blocking agents (Nondepolarizing), may increase the neuromuscular side effects of Corticosteroids. It is possible to experience increased muscle weakness that could lead to myopathies or polyneuropathies.

Polymyxin A

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Risk Factor X (Avoid Combination)

QuiNINE

May increase the neuromuscular-blocking effects of Neuromuscular Blocking Agents.

Monitoring Parameters:

  • Vital signs like heart rate, blood pressure, and respiratory rate.
  • Monitor for muscle movements i.e. the degree of muscle paralysis, ventilator asynchrony, and shivering.

How to administer Atracurium?

  • You should administer it as an intravenous injection in bolus form.
  • Because of tissue irritation, do not give intramuscular injections!
  • You can administer it via continuous intravenous injection via an infusion pump. 
  • After 24 hours, the preparation or solution should be stopped.

Mechanism of action of Atracurium:

  • It blocks neural transmission at a neuromuscular junction by binding to cholinergic receptor sites
  • Dose-dependent, the onset of action takes between 2 and 3 minutes.

The peak effect lasts for 3 to 5 minutes. The initial dose of 0.4-0.5 mg/kg under balanced sedation is sufficient to start recovery.

However, it may take up to 60-70 minutes for greater than 95% power to return. Hypothermia patients may experience a longer duration of action.

It is subject to ester hydrolysis and Hofmann removal. The metabolites are not active and have no neuromuscular-blocking properties. Laudanosine, which acts as a CNS stimulant, is one of the metabolites. It can accumulate over time. 

The liver then converts it to other compounds. The half-life elimination varies with age. It is about 20 minutes in infants, 17 minutes in children, and biphasic in adults (initial 2 minutes and terminal 20 minutes).

Less than 5% of the drug is excreted in the urine.   

International Brands of Atracurium:

  • Acris
  • Acrium
  • Aculex
  • Acurmil
  • Atacure
  • Atra
  • Atracor
  • Atradnor
  • Atralex
  • Atravell
  • Atrium
  • Farelax
  • Genso
  • Notrixum
  • Relaston
  • Relatrac
  • Tarcum
  • Trac
  • Tracrrium
  • Tracur
  • Tracurix
  • Tramus
  • Trarium

Atracurium brands in Pakistan:

 

Atracurium (Besylate) [Inj 10 Mg/Ml]

Acuron

Brookes Pharmaceutical Laboratories (Pak.) Ltd.

Acuron

Brookes Pharmaceutical Laboratories (Pak.) Ltd.

Atramed

Mediceena Pharma (Pvt) Ltd.

Atramed

Mediceena Pharma (Pvt) Ltd.

Curim

Global Pharmaceuticals

Efacurim

Surge Laboratories (Pvt) Ltd.

Efacurim

Surge Laboratories (Pvt) Ltd.

Relaxtron

Zafa Pharmaceutical Laboratories (Pvt) Ltd.

Tracrium

Glaxosmithkline

Tracrium

Glaxosmithkline

Trarium

Hoffman Health Pakistan Ltd.

Trarium

Hoffman Health Pakistan Ltd.

 

Atracurium (Besylate) [Inj 50 Mg/5ml]

Atrelax

Abbott Laboratories (Pakistan) Limited.

Trarium

Hoffman Health Pakistan Ltd.

 

 



 

 

 

Atracurium (Besylate) [Inj 50 Mg/Ml]

A-Care

Caraway Pharmaceuticals

 

Atracurium (Besylate) [Inj 25 Mg/2.5ml]

Atrelax

Abbott Laboratories (Pakistan) Limited.

 

 

 

 

 

 

 

Try Your Luck Here